Key points
- Revenue up 11.6% to $140.3 million
- Underlying EBITDA up 10.7% to $35.6 million
- Underlying NPAT up 5.5% to $15.8 million
Full summary
Monash IVF Group Limited reported a 11.6% increase in revenue to $140.3 million for the first half of FY25, driven by growth across its domestic Australian IVF businesses, international operations, ultrasound services, and day surgery. Underlying EBITDA increased 10.7% to $35.6 million, with the Australian and international segments both delivering EBITDA growth. Underlying NPAT grew 5.5% to $15.8 million. The company's reported NPAT of $17.3 million included certain non-regular items that improved profitability on a net basis by $1.5 million. The balance sheet remained strong, with net debt of $72.5 million and a net debt to equity ratio of 28.5%. Key capital metrics such as return on equity and return on assets also improved compared to the prior period.